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Abstract
Any illness associated with possible immune dysfunction during childhood
requires a decision on the start and/or continuation of ongoing vaccination
program according to national guidelines, as well as the decision on possible
booster vaccination and vaccination with additional, registered vaccines. It is
widely accepted that if a child with presumed or proven immune disorder
might benefit from vaccination, this should not be delayed if its application is
safe. Children with immune disorders vary in the degree of immunosuppres-
sion, susceptibility to infections and immune reactions after vaccination. Be-
sides these, there are certain groups of children with diseases that increase their
risk of infectious diseases even in the absence of specific immune disorders. In
this article, we discuss the basic principles that should guide decisions for im-
munization of children with suspected or proven immune system disorder
(primary or secondary).
During childhood, we obtain the largest number of vaccines. Im-mune disorders resulting from inherited errors of immune system
are rare diseases and very heterogeneous in their degree and type of
immunosuppression, ranging from mild defects in immune function to
severe, life-threatening conditions that usually affect multiple arms of the
immune system (1). However, the advances of modern medicine made
in treatment of malignant and inflammatory diseases and resulting in
improved survival and morbidity rates, increased the proportion of chil-
dren who have special vaccination needs (2). Regardless of the origin of
immune dysfunction, primary or secondary, children vary in the degree
of immunosuppression, susceptibility to infections and immune reac-
tions after vaccination. These differences emphasize the necessity of
careful examination of all three issues of importance in the vaccination
of children: vaccine safety, vaccine efficacy and the potential benefit of
particular vaccines in unique medical circumstances of each immuno-
compromised child (3).
UNDERSTAND YOUR PATIENT’S CONDITION AND
PERFORM CAREFUL ASSESSMENT OF RISKS
VERSUS BENEFITS
To clarify a given child’s immune status, his or her underlying diag-noses need to be considered and the degree of immunosuppression
must be determined. There are at least six different groups of condi-
tions and treatments that should be taken into account prior to any de-
cision to vaccinate a child:
1) Primary immunodeficiency
2) Malignant and other diseases treated with chemotherapy and/or
hemopoietic stem cell transplantation
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Overview
3) Solid organ transplantation
4) Inflammatory disease treated with immunosup-
pressive therapy
5) HIV infection, and
6) Other conditions that increase the risk of infec-
tious diseases even in the absence of specific im-
mune disorders (ie, asplenia/hyposplenism, mal-
nutrition and chronic disease, nephrotic syndrome,
children born prematurely, etc).
Primary immunodeficiency
Primary immunodeficiencies (PID) are a heteroge-
neous group of inherited disorders. Classification of PIDs
needs to be constantly updated as novel developments in
gene discovery and increased knowledge in the mecha-
nisms that govern immune system development and func-
tion help us in the identification of novel PIDs. The most
recent classification of PID recommended by the Inter-
national Union of Immunological Societies Expert Com-
mittee on Primary Immunodeficiency recognizes eight
groups of these disorders: 1) combined immunodefici-
encies, 2) well-defined syndromes with immunodefi-
ciencies, 3) predominantly antibody deficiencies, 4) dis-
eases of immune dysregulation, 5) congenital defects of
phagocytic number, function or both, 6) defects in innate
immunity, 7) autoinflammatory disorders , and 8) com-
plement deficiencies (for details see 4). Figure 1 shows a
simplified algorithm for evaluation of a child with sus-
pected PID based on thorough history as well as clinical
presentation. It should be stressed that not all immuno-
deficiencies are alike and each presents different issues
related to the risk and benefits of vaccines. Furthermore,
the definitive diagnosis of PID that requires the confir-
mation of genetic defect if discovered is often not known
at the time of immunization. Only rarely is immunity so
compromised that active immunization is unsafe, inef-
fective and/or inappropriate. From the immunization
point of view, PIDs can be subdivided into three catego-
ries: severe, moderate and non-specific. Some general
recommendations regarding the immunization practice
in PID patients are shown in Table 1 (1, 4, 5). Live atten-
uated vaccines are contraindicated for all patients who
have combined and T cell mediated disorders. Children
with B cell disorders could be immunized against mea-
sles, mumps, and rubella (MMR), but immunogenicity
of this vaccine is decreased as these children are sched-
uled to receive immunoglobulin regularly (5, 6). Other
live viral vaccines are contraindicated in patients with
this disorder, except in immunoglobulin A deficiency.
Many experts believe that live-virus vaccines are safe to
administer to children who have disorders of phagocyte
or complement function.
Taking into account Mandatory Childhood Vaccina-
tion Program in Croatia, it should be emphasized that
BCG vaccination should be delayed in every newborn
with a family history of primary immunodeficiency until
the condition has been ruled out (7). Furthermore, if a
child with a strong clinical and laboratory suspicion of
severe and/or combined PID has been immunized with
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Figure 1. A simplified algorithm for evaluation of a child with suspected PID based on thorough history, as well as clinical presentation. PID = pri-
mary immunodeficiency.
BCG vaccine, tuberculous prophylaxis with at least two
drugs should be started without delay while awaiting ex-
act diagnosis of immune disorder (8).
Malignant and other diseases treated
with chemotherapy and/or hemopoietic
stem cell transplantation (HSCT)
The degree and type of impairment of immune sys-
tem function during and after treatment for malignant
and other diseases treated with chemotherapy and/or
hemopoietic stem cell transplantation vary considerably
among patients. Factors that should be taken into ac-
count are the nature of disease, type of treatment and the
presence of a functional spleen (9). Regarding children
with malignant disease, no live vaccines should be given:
1) to those undergoing chemotherapy, 2) within six mon-
ths following completion of chemotherapy, and if 3) tu-
mor/disease is not in remission. MMR vaccination should
be further postponed if these children received additional
therapy such as blood derivates and immunoglobulins
(Table 2). A possible exception are children with acute
lymphatic leukemia who might be immunized against
varicella three months after completion of therapy if they
are in remission and have no anti-varicella specific anti-
bodies (two doses of vaccine are recommended), but re-
cently this approach has been questioned regarding its
safety (10, 11).
At six months following completion of treatment, it is
recommended for most of the children in this group to
receive an additional booster of diphtheria (DI), tetanus
(TE), and acellular pertussis if they are less than 8 yrs
old, or DI-TE pro adultis for those =8 years (3). Other
inactivated vaccines should also be given, especially in-
cluding pneumococcal vaccine and conjugated vaccine
against Haemophilus influenza type B (Hib) if children
are less than 5 years old or were splenectomized. Subse-
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TABLE 1
General recommendations for immunization in some PIDs based on severity of presentation.
Common presentation
of immune disorder
Examples of PID General recommendations











Common variable immunodeficiency (CVID)*
1. No live vaccines (including rotavirus vaccine) ex-
cept for some patients with PIDs indicated by aster-
isks since its severity is variable
2. those with mild phenotype might be immunized
with MMR but it is recommended to monitor spe-
cific antibody response after vaccination
3. questionable vaccine response in those on immu-
noglobulin replacement
Moderate IgA deficiency
Most IgG subclass deficiencies
Failure of antibody production to specific vaccines
1. No absolute contraindications for immunization
2. Consider vaccines such as pneumococcal and in-
fluenza vaccines
Non-specific Chronic neutropenia
Chronic granulomatous disease (CGD)
Complement deficiency diseases
Other opsonisation defects
1. BCG vaccine is contraindicated for CGD
2. Other live vaccines seem to be safe
3. Consider vaccines such as pneumococcal and in-
fluenza vaccines
4. consider meningococcal vaccine for patients with
deficiencies of terminal complement components
* Or equivalent doses of other steroids
TABLE 2
Recommended postponement of MMR-vaccine in chil-





Hyperimmune tetanus or varicella serum 3–5
Hyperimmune HBV serum 3
Immunoglobulins (depends on dosage) 8–11
HBV – hepatitis B virus
quent routine booster doses (e.g. pre-school) are usually
not necessary if they are scheduled to be administered
within one year of the additional dose that has been given
six months after treatment completion (3, 9).
The degree and kinetics of immune function recovery
following HSCT are determined by many factors such as
the primary disease, type of conditioning regimen (espe-
cially if T cell depletion was performed), graft types
(autologous or allogeneic), source of cells (bone marrow,
peripheral blood, umbilical cord blood), HLA-compati-
bility between a donor and a recipient, and the degree of
chimerism. Furthermore, most children usually receive
immunosuppressive drugs in order to control graft-ver-
sus-host disease (GVHD). These factors contribute to
weak or even absent immunity in the recipient. Studies
indicate that administration of non-live vaccines such as
diphtheria and tetanus toxoids to the donor before organ
harvest and to the recipient after transplantation can fa-
cilitate response to these antigens. The use of non-live
vaccines is recommended if the patient is not receiving
immunoglobulins. However, the use of live vaccines is
potentially dangerous until the child has been off all
immunosuppressive treatment for at least 12 months and
has no evidence of active chronic GVHD. Some vaccines
are not recommended due to the lack of data regarding
safety and immunogenicity (i.e. intranasal influenza vac-
cine, cholera vaccine, oral typhoid vaccine, zoster vac-
cine, rotavirus vaccine), while some are strictly contrain-
dicated (BCG, oral Polio). The frequency and severity of
loss of immunity appear to be lower in children who have
received an autologous HSCT. However, it has being
shown that these children often become seronegative so
they should be considered for a re-immunization pro-
gram also, usually starting one year post-HSCT. An in-
terested reader will find more details in recently pub-
lished joint guidelines by the European Group of Blood
and Marrow Transplantation (EBMT) and the Centers
for Disease Control (CDC), by the Infectious Diseases
Society of America (IDSA) and by the American Society
for Blood and Marrow Transplantation (ASBMT) pub-
lished in 2009 (12).
Solid organ transplantation
Children being considered for solid organ transplan-
tation should be up to date with routine primary immu-
nizations or scheduled to receive age-recommended im-
munizations prior to transplantation if possible (3). Live
virus vaccines should be administered at least 4 weeks
before organ transplantation to minimize the potential
for post-transplant vaccine-related illness. Some experts
recommend the evaluation of antibody titers to MMR
and varicella to determine if these vaccines are needed
before solid organ transplantation. Liver-transplant can-
didates should be immunized against hepatitis B and
possibly hepatitis A because of the more rapid and severe
course of infection in comparison to other children (13).
After solid organ transplantation, children receiving
chronic immunosuppressive treatment should be given
non-live vaccines normally according to the national im-
munization schedule, but should not receive live vac-
cines. Most experts recommend waiting at least 6 months
after solid organ transplantation for the resumption of
immunization schedules, but this should also be evalu-
ated individually (13, 14).
Inflammatory disease treated with
immunosuppressive therapy
Patients with many inflammatory diseases, irrespec-
tive of their autoimmune or autoinflammatory etiology,
are generally considered to be at increased risk of infec-
tion due to either the nature of their disease or type of
treatment. As in all other immunocompromised chil-
dren, safety of vaccination is in addition to efficacy of un-
questionable importance (15). Whether or not vaccina-
tion raises the incidence of autoimmune diseases or pres-
ents a risk of coincidental temporal association is still un-
der debate (16, 17). Vaccination should ideally be admin-
istered during stable disease. Live-attenuated vaccines
should not be administered if patients are on high-dose
steroids, disease-modifying drugs or biological drugs.
The cut-off values for these drugs are mostly made on
consensus and not occurrence of infections (18, 19). The
dose and duration of systemic steroid treatment that re-
sults in significant immunosuppression are usually con-
sidered to include prednisolone (or equivalent doses of
other steroids) 2 mg/kg/day or equivalent to a total of at
least 20 mg/day for children who weigh more than 10 kg
for more than one week, or 1 mg/kg/day for more than
one month. These children are often on additional or al-
ternative immunosuppressive drugs, such as azathio-
prine, cyclosporin A, methotrexate, and biological agents
which may further compromise the immune function.
Table 3 shows recommendation, based on the currently
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TABLE 3
Consensus-based recommendation to withhold live-at-
tenuated vaccines in pediatric patients with inflammatory
diseases treated with high dosages of common im-
munosuppressive drugs.
Drug Cut-off values of
immunosuppressive drugs
Prednisolone*  2 mg/kg ( 20 mg/day if body
mass >10 kg)  2 weeks
or
1 mg/kg/day for more than one
month
Methotrexate 15 mg/m2/week
Cyclosporin A 2.5 mg/kg/day
Sulphasalazine 40 mg/kg/day – 2g/day
Azathioprine 1–3 mg/kg
Cyclophosphamide 0.5–2.0 mg/kg/day orally
Leflunomide 0.25–0.5 mg/kg/day
6-mercaptopurine 1.5 mg/kg/day
* Or equivalent doses of other steroids
available evidence and expert opinion recently formu-
lated by an EULAR task force, when to withhold live-at-
tenuated vaccines in pediatric patients with inflamma-
tory diseases if they are treated with high dosages of
common immunosuppressive drugs (19). Vaccine sched-
ules should be postponed until corticosteroids have been
discontinued for at least 3 months. The safety and effi-
cacy of live-attenuated vaccines administered concur-
rently with other immunomodulators is unknown and
until additional information becomes available, avoid-
ance of live vaccines is generally recommended. This is
especially important for BCG in patients receiving anti-
-TNF drugs as well as in patients with active Kawasaki
disease.
Patients treated with methotrexate and/or anti-TNF
therapy have an increased risk of severe disseminated
primary varicella infection or zoster infections (10). It is
important that evaluation of possible candidates for such
a treatment include careful history of possible infection
in the past. If this history is negative or inconclusive, it is
advised to first assess humoral immunity and immunize
a child if specific antibodies are negative. The recom-
mended consensus-based guideline is to wait up to 4
weeks before starting treatment with DMARD and/or
anti-TNF therapy. If a child acquires varicella, therapy
with acyclovir and/or varicella-zoster hyperimmune glo-
bulin might be necessary.
Non-live vaccines are generally recommended espe-
cially for these groups although some exceptions in terms
of their efficacy are well-known.
However, influenza vaccination and pneumococcal
vaccination should be strongly considered and it seems
that, in comparison to high or prolonged treatment with
glucocorticoids, their use in patients treated with DMARDs
and TNF-inhibitors, but not rituximab, could be recom-
mended according to available guidelines (20). Routine
vaccination should be finished at least two weeks prior to
initiation of therapy. Table 4 shows available data regard-
ing safety in patients treated with different immunosup-
pressive drugs. Vaccination against human papilloma vi-
rus seems to be safe in patients with juvenile idiopathic
arthritis (19). It is also advised to immunize adolescent
girls with stable systemic lupus erythematosus with this
vaccine, although a caution is necessary as HPV-vaccine
has been linked to increased incidence of venous throm-
boembolic events (21). A recent study performed in adults
18–35 years old showed that this vaccine is well tolerated
and reasonably effective in patients with stable SLE and
does not induce an increase in lupus activity or flares
(22).
In conclusion, it is recommended to keep to expert
consensus guidelines while maintaining strict surveil-
lance and submitting reports of possible side effects fol-
lowing any vaccine administration.
HIV infection
A decision to immunize a HIV-positive child should
be based on child’s age, numbers of CD4+ T cells and
risk for infection (2, 3). It seems that most of the non-live
vaccines are efficacious if children are undergoing ther-
apy, have un detectable or low copy HIV number, no
lymphopenia and no decreased number of CD4+ T
cells. Subunit influenza vaccine seems to be safe even in
symptomatic patients although reports of increased HIV
viral copies have been described following influenza vac-
cination. Data from the literature shows that some live-
-attenuated vaccines such as MRP and VZV are safe if a
child has normal number of CD4+ T cells, but BCG
vaccine is usually contraindicated (23).
Other conditions that increase the
risk of infectious diseases even in the
absence of specific immune disorders
Many conditions pose a risk of infection for a child.
This is particularly important for children with func-
tional or anatomic asplenia who are at increased risk of
invasive infections with encapsulated bacteria such as
Streptococcus pneumonia, Neisseria meningitidis and Hib.
Therefore, these children should be immunized with the
Hib-vaccine as well as pneumococcal (depending of child’s
age 7-heptavalent conjugate pneumococcal vaccine be-
fore age 2, or the 23-valent pneumococcal polysaccharide
vaccine for older children) and meningococcal vaccine. If
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TABLE 4
Safe non-live vaccines in patients with inflammatory diseases undergoing therapy.
Drug Safety demonstrated for the following vaccines
Glucocorticosteroids1 HBV, influenza, pneumococcal
Methotrexate2 HBV, influenza, TT*
Anti-TNF-alpha Influenza, pneumococcal
Rituximab3 Influenza, pneumococcal, TT
Tocilizumab (anti-IL-6) Influenza
1 studied in children treated with maximum dose of 10 mg/day of prednisolone
2 < 15 mg/m2/week
3 it is highly recomended to immunize a child BEFORE therapy with rituximab; immunization with influenza and TT should be
postponed six months after completion of therapy
* TT = tetanus toxoid vaccine
an elective splenectomy is planned, it is important to en-
sure that the child is up to date with Hib and me-
ningococcal C conjugate vaccinations, and has received
pneumococcal vaccination as far in advance as possible
(24). Children with chronic disease and malnutrition
such as those with cystic fibrosis or children with ne-
phritic syndrome should also receive pneumococcal vac-
cine, as well as influenza vaccine. Children with the
nephrotic syndrome often receive corticosteroids or other
immunosuppressive treatment so, for them, similar rec-
ommendations as described for children with inflamma-
tory diseases should be applied. Children born prema-
turely respond appropriately to most immunizations, but
there is some evidence that a minority may fail to re-
spond adequately to hepatitis B immunizations if this
vaccine is given at birth to infants under 2 kg birth weight
(25). Premature infants 6 months of age or older and ex-
periencing chronic lung disease have to be vaccinated
against influenza (24).
UNDERSTAND THE VACCINE
AND KNOW THE CURRENT
VACCINE RECOMMENDATIONS
Understanding immunization principles and strate-
gies for children who are immunocompromised is criti-
cally important to maximize protection against prevent-
able diseases. The most up-to-date recommendations on
vaccinations in immunocompetent children are easily
accessible on several international web-sites such as the
web-site of Centers for Disease Control and Prevention.
However, this is not the case for all immunocompro-
mised patients. In addition to immunogenicity, recom-
mendations concerning the immunization of immuno-
compromised children must take into account safety pro-
file, possible effect on the underlying disease and control
of infections (Table 5). Most recommendations are con-
sensus based, as controlled studies especially in terms of
possible safety profile of particular vaccine, are absent.
Many issues regarding possible effect of therapy are also
unresolved. For example, it is not known to what extent
and which dosage of immunoglobulin supplementation
interferes with vaccine immunogenicity (5). This is par-
ticularly important for patients with B cell disorders as
regular immunoglobulin therapy is the mainstay for pre-
vention of infection in this group of immunocompro-
mized patients. Correlates of immunological response
following vaccination, as well as the development of
memory cells have not been established for all vaccines
and a simple measurement of specific antibodies is not
sufficient for evaluation of vaccine efficiency. The neces-
sity to re-immunize children because of waning immu-
nity is also unresolved for many immunocompromised
children. A recent introduction of a rotavirus vaccine
once again raised the level of awareness regarding safety
of vaccines. Postmarketing reports have described severe
gastroenteritis with vaccine viral shedding in infants who
received rotavirus vaccine and were later diagnosed with
severe combined immunodeficiency (26). Timely identi-
fication of children with severe types of primary immu-
nodeficiency (e.g., from expanded newborn screening or
improved clinical awareness) could prevent unsafe live
vaccine administration and many complications linked
to vaccine-related illness. As stressed already in this arti-
cle, it is important to keep to expert consensus guidelines
if they exist while maintaining strict surveillance and
submitting reports of possible side effects. This is par-
ticularly important because of possible changes in na-
tional vaccination program as well as emerging results
from studies about safety and efficacy of existing and
new vaccines.
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TABLE 5
Special considerations in immunocompromised children for inactivated (non-live) vaccines (adopted from Nield SL, Troischt
MJ. Vaccinating the Immunocompromised Child, 2009. »New Football Recruits.« Northwestern Football. Ed. Alex Shokey.
2004. Northwestern University. 2 Oct 2009 <http://www.pediatricsconsultantlive.com/display/article/1803329/1466353 >)
Type of licenced vaccine Special considerations in immunocompromised children
Di-Te-aP Tetanus toxoid less efficient in children with AIDS?
Hib Recommended for children with asplenia
HAV Immunize seronegative patients, liver transplant recipients and those with chronic liver disease
HBV Immunize seronegative patients, liver transplant recipients and those with chronic liver disease
HPV Children with syndrome WHIM
Influenza Use subunit vaccine
Immunize infants  6 months of age
iPolio
Meningococcal Recommended for children with asplenia and deficiencies of terminal complement components
Pneumococcal <10 yrs 7vPCV
 10 yrs 23vPCV
WHIM – warts, hypogammaglobulinemia, myelokathesis; CVID – combined variable immunodeficiency; 7vPCV – 7-valent
Pneumococcal Conjugated Vaccine; 23vPCV – 23-valent Pneumococcal Conjugated Vaccine
IMMUNIZE CONTACTS
One strategy worth emphasizing is the protection of
immunosuppressed children from vaccine-preventable
diseases by immunization of household contacts, partic-
ularly other children and adolescents in the family (27).
Annual influenza vaccination of all family members
with inactivated influenza vaccine is recommended in
addition to ensuring routine immunization of all other
recommended vaccines. MMR, varicella, and rotavirus
vaccines, although live viral vaccines, are recommended
for immunocompetent household contacts because trans-
mission of the virus is rare. However, one should bear in
mind that house-hold contacts must be properly infor-
med when and how the transmission could take place.
For example, varicella virus can be shed through a post-
immunization vesicular rash so a contact with an im-
munocompromised child should be strictly avoided until
the rash resolves. For the rotavirus vaccine, an immuno-
compromised child should at least one week after vacci-
nation not be in in contact with the stool of a vaccinated
household contact so that hand hygiene is of utmost im-
portance. Other live-attenuated vaccines, especially BCG,
are contraindicated for household contacts (27).
WHENEVER IN DOUBTS, CONSIDER A
SUBSPECIALIST
Even if recommendations for a particular group of
immunocompromised children are up-to-date, primary
care physicians are placed under great pressure when a
decision to immunize a child should be made. As we of-
ten see in everyday clinical practice, a subspecialist in-
cluded in the specific treatment of a child as well as other
subspecialists are usually consulted in order to define an
optimal individual vaccination plan. This approach is
welcome in order to determine the child’s actual risk of
acquiring natural infection and of experiencing compli-
cations from a vaccine-preventable infection, as well as
the risk associated with vaccine administration. It is nec-
essary to emphasize that a particular child with immune
disorder has the benefit of vaccination, so it cannot be de-
layed or not implemented, provided that its application is
safe. Besides the application of existing vaccines, im-
munocompromised children need vaccines with impro-
ved immunogenicity, as well as new vaccines against seve-
ral microorganisms that cause a disease in immunocom-
promised host. It is also necessary to introduce better corre-
lates of immunity after vaccination and develop methods
for their analysis that are applicable in clinical practice.
REFERENCES
1. TAMMA P 2010 Vaccines in immunocompromised patients. Pediatr
Rev 31: 38–40
2. WEBER D J, RUTALA W A 2003 Immunization of immuno-
compromised persons. Immunol Allergy Clin North Am 23: 605–34
3. ABZUG M J 2009 Vaccination in the immunocompromised child: a
probe of immune reconstitution. Pediatr Infect Dis J 28: 233–6
4. AL-HERZ W, BOUSFIHA A, CASANOVA J L, CHAPEL H,
CONLEY M E, CUNNINGHAM-RUNDLES C, ETZIONI A,
FISCHER A, FRANCO J L, GEHA R S, HAMMARSTRÖM L,
NONOYAMA S, NOTARANGELO L D, OCHS H D, PUCK J M,
ROIFMAN C M, SEGER R, TANG M L 2011 Primary immunode-
ficiency diseases: an update on the classification from the
International Union of Immunological Societies Expert Committee
for Primary Immunodeficiency. Front Immunol 2: 54
5. NATIONAL CENTER FOR IMMUNIZATION AND RESPI-
RATORY DISEASES 2011 General recommendations on immuni-
zation – recommendations of the Advisory Committee on Immuni-
zation Practices (ACIP). MMWR Recomm Rep 60: 1–64
6. NAHIRNIAK S, HUME HA 2010 Guidelines for the use of immu-
noglobulin therapy for primary immune deficiency and solid organ
transplantation. Transfus Med Rev 24 Suppl 1: S1-6
7. NOROUZI S, AGHAMOHAMMADI A, MAMISHI S, ROSENZ-
WEIG S D, REZAEI N 2012 Bacillus Calmette-Guérin (BCG)
complications associated with primary immunodeficiency diseases. J
Infect 64: 543–54
8. REZAI M S, KHOTAEI G, MAMISHI S, KHEIRKHAH M,
PARVANEH N 2008 Disseminated Bacillus Calmette-Guerin in-
fection after BCG vaccination. J Trop Pediatr 54: 413–6
9. RUGGIERO A, BATTISTA A, COCCIA P, ATTINÀ G, RICCAR-
DI R 2011 How to manage vaccinations in children with cancer.
Pediatr Blood Cancer 57: 1104–8
10. WIEGERING V, SCHICK J, BEER M, WEISSBRICH B, GAT-
TENLÖHNER S, GIRSCHICK H J, LIESE J, SCHLEGEL P G,
EYRICH M 2011 Varicella-zoster virus infections in immunocom-
promised patients – a single centre 6-year analysis. BMC Pediatr 11: 31
11. CANIZA M A, HUNGER S P, SCHRAUDER A, VALSECCHI
MG, PUI C H, MASERA G, MEMBERS OF INTERNATIONAL
STUDY GROUP OF CHILDHOOD ALL ( »PONTE DI LEG-
NO WORKING GROUP«) 2012 The controversy of varicella vacci-
nation in children with acute lymphoblastic leukemia. Pediatr Blood
Cancer 58: 12–6
12. LJUNGMAN P, CORDONNIER C, EINSELE H, ENGLUND J,
MACHADO C M, STOREK J, SMALL T 2009 Vaccination of
hematopoietic cell transplant recipients. Bone Marrow Transplant 44:
521–6
13. ABUALI M M, ARNON R, POSADA R 2011 An update on immu-
nizations before and after transplantation in the pediatric solid organ
transplant recipient. Pediatr Transplant 15: 770–7
14. ALLEN U, GREEN M 2010 Prevention and treatment of infectious
complications after solid organ transplantation in children. Pediatr
Clin North Am 57: 459–79
15. BIJL M, AGMON-LEVIN N, DAYER J M, ISRAELI E, GATTO
M, SHOENFELD Y 2012 Vaccination of patients with auto-im-
mune inflammatory rheumatic diseases requires careful benefit-risk
assessment. Autoimmun Rev 11: 572–6
16. SHOENFELD Y, AGMON-LEVIN N 2011 'ASIA' – autoimmune/
inflammatory syndrome induced by adjuvants. J Autoimmun 36: 4–8
17. KOENIG H C, SUTHERLAND A, IZURIETA H S, MCGONA-
GLE D 2011 Application of the immunological disease continuum
to study autoimmune and other inflammatory events after vaccina-
tion. Vaccine 29: 913–9
18. HEIJSTEK M W, OTT DE BRUIN L M, BORROW R, VAN DER
KLIS F, KONÉ-PAUT I, FASTH A, MINDEN K, RAVELLI A,
ABINUN M, PILEGGI G, BORTE M, BIJL M, WULFFRAAT N
M 2011 Vaccination in paediatric patients with auto-immune rheu-
matic diseases: a systemic literature review for the European League
against Rheumatism evidence-based recommendations. Autoimmun
Rev11: 112–22
19. HEIJSTEK M W, OTT DE BRUIN L M, BIJL M, BORROW R,
VAN DER KLIS F, KONÉ-PAUT I, FASTH A, MINDEN K,
RAVELLI A, ABINUN M, PILEGGI G S, BORTE M, WUL-
FFRAAT N M, EULAR 2011 EULAR recommendations for vacci-
nation in paediatric patients with rheumatic diseases. Ann Rheum
Dis 70: 1704–12
20. PESCOVITZ M D, TORGERSON T R, OCHS H D, OCHEL-
TREE E, MCGEE P, KRAUSE-STEINRAUF H, LACHIN J M,
CANNIFF J, GREENBAUM C, HEROLD K C, SKYLER J S,
WEINBERG A; TYPE 1 DIABETES TRIALNET STUDY GROUP
2011 Effect of rituximab on human in vivo antibody immune re-
sponses. J Allergy Clin Immunol 128: 1295–1302
21. SLADE B A, LEIDEL L, VELLOZZI C, WOO E J, HUA W,
SUTHERLAND A, IZURIETA H S, BALL R, MILLER N, BRAUN
M M, MARKOWITZ L E, ISKANDER J 2009 Postlicensure safety
surveillance for quadrivalent human papillomavirus recombinant
vaccine. JAMA 302: 750–7
Period biol, Vol 114, No 2, 2012. 173
Vaccinating an Immunocompromised Child Alenka Gagro
22. MOK C C, HO LY, FONG L S, TO C H 2012 Immunogenicity and
safety of a quadrivalent human papillomavirus vaccine in patients
with systemic lupus erythematosus: a case-control study. Ann Rheum
Dis (in press)
23. MOFENSON L M, BRADY M T, DANNER S P, DOMINGUEZ
K L, HAZRA R, HANDELSMAN E, HAVENS P, NESHEIM S,
READ J S, SERCHUCK L, VAN DYKE R 2009 Guidelines for the
Prevention and Treatment of Opportunistic Infections among HIV-
-exposed and HIV-infected children: recommendations from CDC,
the National Institutes of Health, the HIV Medicine Association of
the Infectious Diseases Society of America, the Pediatric Infectious
Diseases Society, and the American Academy of Pediatrics. MMWR
Recomm Rep 58: 1–166
24. WALMSLEY D 2011 Routine pediatric immunization, special cases
in pediatrics: prematurity, chronic disease, congenital heart disease:
recent advancements/changes in pediatric vaccines. Prim Care 38:
595–609
25. LINDER N, VISHNE TH, LEVIN E, HANDSHER R, FINK-
-KREMER I, WALDMAN D, LEVINE A, ASHKENAZI S, SI-
ROTA L 2002 Hepatitis B vaccination: long-term follow-up of the
immune response of preterm infants and comparison of two vacci-
nation protocols. Infection 30: 136–9
26. CENTERS FOR DISEASE CONTROL AND PREVENTION
(CDC) 2010 Addition of severe combined immunodeficiency as a
contraindication for administration of rotavirus vaccine. MMWR
Morb Mortal Wkly Rep 59: 687–8
27. LESSIN H R, EDWARDS K M, COMMITTEE ON PRACTICE
AND AMBULATORY MEDICINE; COMMITTEE ON INFEC-
TIOUS DISEASES 2012 Immunizing parents and other close fam-
ily contacts in the pediatric office setting. Pediatrics 129: e247–53
174 Period biol, Vol 114, No 2, 2012.
Alenka Gagro Vaccinating an Immunocompromised Child
